A detailed history of Raymond James & Associates transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 20,000 shares of SNSE stock, worth $9,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 14,000 42.86%
Holding current value
$9,800
Previous $8,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$0.48 - $0.72 $2,880 - $4,320
6,000 Added 42.86%
20,000 $12,000
Q1 2023

Apr 14, 2023

SELL
$1.31 - $1.7 $6,550 - $8,500
-5,000 Reduced 26.32%
14,000 $21,000
Q2 2022

Aug 12, 2022

BUY
$1.49 - $2.3 $8,940 - $13,799
6,000 Added 46.15%
19,000 $43,000
Q1 2022

May 11, 2022

BUY
$2.22 - $6.07 $28,860 - $78,910
13,000 New
13,000 $30,000

Others Institutions Holding SNSE

About Sensei Biotherapeutics, Inc.


  • Ticker SNSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,720,300
  • Market Cap $15.1M
  • Description
  • Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...
More about SNSE
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.